Crystalline forms of a known pyrrolidine factor xa inhibitor

Details Crystalline forms of a known pyrrolidine factor xa inhibitor Crystalline forms of a known pyrrolidine factor xa inhibitor

C - Chemistry, Metallurgy

07

D

C07D 401/12 (2006.01) A61P 7/02 (2006.01)

Patent

CA 2602550

Disclosed are crystalline forms A, B and C of 1 ,2-Pyrrolidinedicarboxamide, N1 -(4- chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1 (2H)-pyridinyl)phenyÊ]-4-methoxy- , (2R,4R)- (9Cl). These crystalline forms are characterized by their powder X- ray diffraction, solid-state NMR, as well as methods for the preparation and pharmaceutical compositions of the same which are useful for the treatment of acute, subacute, or chronic thrombotic disorders including treatment of venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, atherosclerosis, angina, primary and secondary deep vein thrombosis, thromboembolism associated with cardiovascular disease, including, but not limited to, acute coronary syndrome, atrial fibrillation, cardiac valve replacement and deep vein thrombosis. The crystalline forms of the present invention are also useful for the treatment of cancer, sepsis and diabetes.

L'invention concerne les formes cristallines A, B et C de 1,2-Pyrrolidinedicarboxamide, N1 -(4- chlorophényl)-N2-[2-fluoro-4-(2-oxo-1 (2H)-pyridinyl)phényl]-4-méthoxy-, (2R,4R)- (9Cl). Ces formes cristallines sont caractérisées par leur diffraction des rayons X sur poudre et par leur RMN en phase solide. L'invention concerne également des procédés de préparation de ces formes cristallines, et des compositions pharmaceutiques de ces formes cristallines, qui peuvent servir au traitement des troubles thrombotiques aigus, subaigus ou chroniques, notamment au traitement des thromboses veineuses, des thromboses artérielles, des embolies pulmonaires, des infarctus du myocarde, des infarctus cérébraux, des resténoses, de l'athérosclérose, de l'angine de poitrine, des thromboses veineuses profondes primaires et secondaires, des thromboembolies associées à des maladies cardiovasculaires, notamment mais non exclusivement au syndrome coronarien aigu, à la fibrillation auriculaire, au remplacement des valvules cardiaques, et aux thromboses veineuses profondes. Les formes cristallines décrites conviennent également pour le traitement du cancer, des sepsies et du diabète.

Affiliated with

Also associated with

Rating

Crystalline forms of a known pyrrolidine factor xa inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline forms of a known pyrrolidine factor xa inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline forms of a known pyrrolidine factor xa inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2087895